The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Apolipoprotein E4 Causes Age- and Tau-Dependent Impairment of GABAergic Interneurons, Leading to Learning and Memory Deficits in Mice
Open accessAbstract
Apolipoprotein E4 (apoE4) is the major genetic risk factor for Alzheimer's disease. However, the underlying mechanisms are unclear. We found that female apoE4 knock-in (KI) mice had an age-dependent decrease in hilar GABAergic interneurons that correlated with the extent of learning and memory deficits, as determined in the Morris water maze, in aged mice. Treating apoE4-KI mice with daily peritoneal injections of the GABA A receptor potentiator pentobarbital at 20 mg/kg for 4 weeks rescued the learning and memory deficits. In neurotoxic apoE4 fragment transgenic mice, hilar GABAergic interneuron loss was even more pronounced and also correlated with the extent of learning and memory deficits. Neurodegeneration and tauopathy occurred earliest in hilar interneurons in apoE4 fragment transgenic mice; eliminating endogenous Tau prevented hilar GABAergic interneuron loss and the learning and memory deficits. The GABA A receptor antagonist picrotoxin abolished this rescue, while pentobarbital rescued learning deficits in the presence of endogenous Tau. Thus, apoE4 causes age- and Tau-dependent impairment of hilar GABAergic interneurons, leading to learning and memory deficits in mice. Consequently, reducing Tau and enhancing GABA signaling are potential strategies to treat or prevent apoE4-related Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It exacerbates AD-related pathologies, including amyloid-beta (Aβ) plaques, Tau tangles, neurodegeneration and neuroinflammation4–16.”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies with mouse (Andrews-Zwilling et al., 2010) and hiPSC-based (Wang et al., 2018) systems have shown that APOE genotypes might influence GABAergic interneuron generation and survival.”
From Isogenic human stem cell models reveal mutation-dependent protective mechanisms of APOE3 Christchurch (2026) · cites this paper as Andrews-Zwilling et al., 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 knock-in (KI) mice exhibit an age-dependent loss of hilar GABAergic interneurons and deficits in learning and memory, which is more profound when the mice express neurotoxic apoE fragments”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Andrews-Zwilling et al 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tau is believed to play a key role in APOE4-related neuronal alterations during aging, as APOE4 leads to age- and Tau-dependent impairment of hilar GABAergic interneurons, resulting in learning and memory deficits in mice [75].”
The cited source says what the claim attributes to it.
In the citing paper
“and is associated with spatial learning and memory impairments [22].”
From Arf4 Determines Dentate Gyrus-Mediated Pattern Separation by Regulating Dendritic Spine Development (2012) · cites this paper as [22]
In the citing paper
“For example, both apoE4 transgenic and apoE4-KI mice show age- and sex-dependent learning and memory deficits in the absence of Aβ accumulation, as compared to apoE3 transgenic and apoE3-KI mice [68–71].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [71]
In the citing paper
“In particular, GABAergic interneurons in the dentate gyrus (DG) are particularly vulnerable to apoE4 fragment-mediated neurotoxicity, and in apoE4 fragment transgenic mice, knocking out tau rescues GABAergic interneuron loss as well as learning and memory deficits, demonstrating the tau-dependent nature of apoE4-induced cognitive impairment [71].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [71]
In the citing paper
“For example, apoE4-KI mice display an age- and tau-dependent decrease in hilar GABAergic somatostatin-positive interneurons in the hippocampus [71].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Mechanisms and Functional Implications of Adult Neurogenesis
Zhao, C., Deng, W., & Gage, F. H. (2008) · Cell · doi:10.1016/j.cell.2008.01.033 · Cited by 3,007
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
Distinct patterns of brain activity in young carriers of the APOE -ε4 allele
Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., Smith, S. M., Matthews, P. M., Beckmann, C. F., & Mackay, C. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811879106 · Cited by 1,613
Cited by
Sorted by citations
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Self-citationApolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Network abnormalities and interneuron dysfunction in Alzheimer disease
Palop, J. J., & Mucke, L. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.141 · Cited by 1,022
Hippocampal GABAergic Inhibitory Interneurons
Pelkey, K. A., Chittajallu, R., Craig, M. T., Tricoire, L., Wester, J. C., & McBain, C. J. (2017) · Physiological Reviews · doi:10.1152/physrev.00007.2017 · Cited by 889
Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment
Bakker, A., Krauss, G. L., Albert, M., Speck, C. L., Jones, L. R., Stark, C. E. L., Yassa, M. A., Bassett, S. S., Shelton, A. L., & Gallagher, M. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.023 · Cited by 940
Morris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899
Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases
Huang, Y., & Mahley, R. W. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.025 · Cited by 829
Self-citationApolipoprotein E: from cardiovascular disease to neurodegenerative disorders
Mahley, R. W. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1427-y · Cited by 837
Epileptic activity in Alzheimer’s disease: Causes and clinical relevance
Vossel, K. A., Tartaglia, M. C., Nygaard, H. B., Zeman, A. Z., & Miller, B. L. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30044-3 · Cited by 590
Incidence and impact of subclinical epileptiform activity in Alzheimer’s disease.
Vossel, K. A., Ranasinghe, K. G., Beagle, A. J., Mizuiri, D., Honma, S. M., Dowling, A. F., Darwish, S. M., Van Berlo, V., Barnes, D. E., Mantle, M., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24794 · Cited by 557
Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism
Mahley, R. W. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307023 · Cited by 516
Wang, C., Ward, M. E., Chen, R., Liu, K., Tracy, T. E., Chen, X., Xie, M., Sohn, P. D., Ludwig, C., Meyer-Franke, A., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.08.019 · Cited by 400
Wang, C., Najm, R., Xu, Q., Jeong, D.-E., Walker, D., Balestra, M. E., Yoon, S. Y., Yuan, H., Li, G., Miller, Z. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0004-z · Cited by 428
Self-citationApolipoprotein e sets the stage: response to injury triggers neuropathology
Mahley, R. W., & Huang, Y. (2012) · Neuron · doi:10.1016/j.neuron.2012.11.020 · Cited by 412
Self-citationGWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease
Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., Benitez, B. A., Jeng, A. T., Skorupa, T., Carrell, D., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.026 · Cited by 383
Tau Protein Modifications and Interactions: Their Role in Function and Dysfunction
Mietelska‐Porowska, A., Wasik, U., Goras, M., Filipek, A., & Niewiadomska, G. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034671 · Cited by 431
Apolipoprotein E in Alzheimer's Disease: An Update
Yu, J.-T., Tan, L., & Hardy, J. (2014) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071013-014300 · Cited by 394
Synaptopathies: synaptic dysfunction in neurological disorders – A review from students to students
Lepeta, K., Lourenco, M. V., Schweitzer, B. C., Martino Adami, P. V., Banerjee, P., Catuara‐Solarz, S., de La Fuente Revenga, M., Guillem, A. M., Haidar, M., Ijomone, O. M., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13713 · Cited by 386
Impairments of neural circuit function in Alzheimer's disease
Busche, M. A., & Konnerth, A. (2016) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2015.0429 · Cited by 360
Antisense Reduction of Tau in Adult Mice Protects against Seizures
DeVos, S. L., Goncharoff, D. K., Chen, G., Kebodeaux, C. S., Yamada, K., Stewart, F. R., Schuler, D. R., Maloney, S. E., Wozniak, D. F., Rigo, F., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2107-13.2013 · Cited by 311
Shinohara, M., Tachibana, M., Kanekiyo, T., & Bu, G. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075796 · Cited by 297
Changes in Brain Function Occur Years before the Onset of Cognitive Impairment
Beason‐Held, L. L., Goh, J. O. S., An, Y., Kraut, M. A., O’Brien, R., Ferrucci, L., & Resnick, S. M. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1402-13.2013 · Cited by 301
Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
Bakker, A., Albert, M., Krauss, G. L., Speck, C. L., & Gallagher, M. (2015) · NeuroImage Clinical · doi:10.1016/j.nicl.2015.02.009 · Cited by 295
Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
Neuronal hyperactivity--A key defect in Alzheimer’s disease?
Busche, M. A., & Konnerth, A. (2015) · BioEssays · doi:10.1002/bies.201500004 · Cited by 266
Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies
Chang, C.-W., Shao, E., & Mucke, L. (2021) · Science · doi:10.1126/science.abb8255 · Cited by 263
Bi, D., Wen, L., Wu, Z., & Shen, Y. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12088 · Cited by 232
Ungar, L., Altmann, A., & Greicius, M. D. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9272-x · Cited by 246
Apolipoprotein E and Alzheimer’s disease: Findings, hypotheses, and potential mechanisms
Koutsodendris, N., Nelson, M. R., Rao, A., & Huang, Y. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-030421-112756 · Cited by 231
Self-citationHolth, J. K., Bomben, V. C., Reed, J. G., Inoue, T., Younkin, L., Younkin, S. G., Pautler, R. G., Botas, J., & Noebels, J. L. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.3191-12.2013 · Cited by 238
Rescue of long-range circuit dysfunction in Alzheimer's disease models
Busche, M. A., Kekuš, M., Adelsberger, H., Noda, T., Förstl, H., Nelken, I., & Konnerth, A. (2015) · Nature Neuroscience · doi:10.1038/nn.4137 · Cited by 221
Cell type‐specific roles of APOE4 in Alzheimer disease
Blumenfeld, J., Yip, O., Kim, M. J., & Huang, Y. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00776-9 · Cited by 202
Self-citationGABAergic Inhibitory Interneuron Deficits in Alzheimer’s Disease: Implications for Treatment
Xu, Y., Zhao, M., Han, Y., & Zhang, H. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00660 · Cited by 203
Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
Molecular aspects of age-related cognitive decline: the role of GABA signaling
McQuail, J. A., Frazier, C. J., & Bizon, J. L. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.05.002 · Cited by 207
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease
Najm, R., Jones, E. A., & Huang, Y. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0324-6 · Cited by 183
Self-citationUpdates on mouse models of Alzheimer’s disease
Zhong, M. Z., Peng, T., Duarte, M. L., Wang, M., & Cai, D. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00712-0 · Cited by 189
Mitochondrial Dysfunction in Alzheimers Disease: Opportunities forDrug Development
Bhatia, S., Rawal, R., Sharma, P., Singh, T., Singh, M., & Singh, V. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210517114016 · Cited by 209
Zalocusky, K. A., Najm, R., Taubes, A. L., Hao, Y., Yoon, S. Y., Koutsodendris, N., Nelson, M. R., Rao, A., Bennett, D. A., Bant, J., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00851-3 · Cited by 189
Self-citationGillespie, A. K., Jones, E. A., Lin, Y.-H., Karlsson, M. P., Kay, K., Yoon, S. Y., Tong, L. M., Nova, P., Carr, J. S., Frank, L. M., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.009 · Cited by 187
Self-citationJiménez-Baladó, J., & Eich, T. S. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.01.005 · Cited by 194
Alzheimer's Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function
Battista, A. M. D., Heinsinger, N. M., & Rebeck, G. W. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160401115127 · Cited by 188
Liu, Y., Cheng, A., Li, Y.-J., Yang, Y., Kishimoto, Y., Zhang, S., Wang, Y., Wan, R., Raefsky, S. M., Lu, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09897-1 · Cited by 176
Beagle, A. J., Darwish, S. M., Ranasinghe, K. G., La, A. L., Karageorgiou, E., & Vossel, K. A. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170031 · Cited by 173
Bien-Ly, N., Gillespie, A. K., Walker, D., Yoon, S. Y., & Huang, Y. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0033-12.2012 · Cited by 170
Self-citationAntisense oligonucleotides: treating neurodegeneration at the level of RNA
DeVos, S. L., & Miller, T. M. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0194-5 · Cited by 164
Ligand-Gated Ion Channels: New Insights into Neurological Disorders and Ligand Recognition
Lemoine, D., Jiang, R., Taly, A., Chataigneau, T., Specht, A., & Grütter, T. (2012) · Chemical Reviews · doi:10.1021/cr3000829 · Cited by 176
Harris, S. S., Wolf, F., De Strooper, B., & Busche, M. A. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.005 · Cited by 161
Episodic memory on the path to Alzheimer's disease
Gallagher, M., & Koh, M. T. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.10.021 · Cited by 166
Zheng, J., Li, H., Tian, N., Liu, F., Wang, L., Yin, Y., Yue, L., Ma, L., Wan, Y., & Wang, J. (2020) · Cell stem cell · doi:10.1016/j.stem.2019.12.015 · Cited by 160
Role of GABAB receptors in learning and memory and neurological disorders
Heaney, C. F., & Kinney, J. W. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.01.007 · Cited by 162
Flowers, S. A., & Rebeck, G. W. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104724 · Cited by 149
Tzioras, M., Davies, C., Newman, A., Jackson, R., & Spires‐Jones, T. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12529 · Cited by 147
Tau reduction prevents disease in a mouse model of Dravet syndrome
Gheyara, A. L., Ponnusamy, R., Djukic, B., Craft, R. J., Ho, K., Guo, W., Finucane, M. M., Sanchez, P. E., & Mucke, L. (2014) · Annals of Neurology · doi:10.1002/ana.24230 · Cited by 138
Pre‐synaptic C‐terminal truncated tau is released from cortical synapses in Alzheimer's disease
Sokolow, S., Henkins, K. M., Bilousova, T., Gonzalez, B., Vinters, H. V., Miller, C. A., Cornwell, L., Poon, W. W., & Gylys, K. H. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.12991 · Cited by 133
Rodriguez, G. A., Burns, M. P., Weeber, E. J., & Rebeck, G. W. (2013) · Learning & Memory · doi:10.1101/lm.030031.112 · Cited by 146
Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits
Koutsodendris, N., Blumenfeld, J., Agrawal, A., Traglia, M., Grone, B., Zilberter, M., Yip, O., Rao, A., Nelson, M. R., Hao, Y., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00368-3 · Cited by 132
Self-citationMahley, R. W., & Huang, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008618 · Cited by 132
Self-citationLevenga, J., Krishnamurthy, P., Rajamohamedsait, H. B., Wong, H., Franke, T. F., Cain, P., Sigurdsson, E. M., & Hoeffer, C. A. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-34 · Cited by 131
Tong, L. M., Djukic, B., Arnold, C., Gillespie, A. K., Yoon, S. Y., Wang, M. M., Zhang, O., Knoferle, J., Rubenstein, J. L. R., Alvarez-Buylla, A., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0693-14.2014 · Cited by 123
Self-citationKazim, S. F., Seo, J. H., Bianchi, R., Larson, C. S., Sharma, A., Wong, R. K. S., Gorbachev, K., & Pereira, A. C. (2021) · eNeuro · doi:10.1523/eneuro.0418-20.2020 · Cited by 120
The dendritic hypothesis for Alzheimer's disease pathophysiology
Cochran, J. N., Hall, A. M., & Roberson, E. D. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.12.004 · Cited by 114
Nelson, M. R., Liu, P., Agrawal, A., Yip, O., Blumenfeld, J., Traglia, M., Kim, M. J., Koutsodendris, N., Rao, A., Grone, B., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01480-8 · Cited by 120
Self-citationLiraz, O., Boehm-Cagan, A., & Michaelson, D. M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-16 · Cited by 118
Hilar interneuron vulnerability distinguishes aged rats with memory impairment
Spiegel, A. M., Koh, M. T., Vogt, N. M., Rapp, P. R., & Gallagher, M. (2013) · The Journal of Comparative Neurology · doi:10.1002/cne.23367 · Cited by 117
Taubes, A., Nova, P., Zalocusky, K. A., Kosti, I., Bicak, M., Zilberter, M. Y., Hao, Y., Yoon, S. Y., Oskotsky, T., Pineda, S., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00122-7 · Cited by 118
Self-citationKoh, M. T., Rosenzweig-Lipson, S. J., & Gallagher, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.023 · Cited by 116
Age-appropriate cognition and subtle dopamine-independent motor deficits in aged Tau knockout mice
Morris, M., Hamto, P., Adame, A., Devidze, N., Masliah, E., & Mucke, L. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.003 · Cited by 117
Synaptic Elimination in Neurological Disorders
Cardozo, P. L., de Lima, I. B. Q., Maciel, E. M. A., Silva, N. C., Dobránsky, T., & Ribeiro, F. M. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190603170511 · Cited by 115
Ambegaokar, S. S., & Jackson, G. R. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr432 · Cited by 113
“Transgenic mice that express full or truncated human APOE4 show increased tau phosphorylation and PHF-like filaments (253– 255), and APOE knockout mice show tau-dependent neurodegeneration (256).”
BackgroundLeung, L., Andrews-Zwilling, Y., Yoon, S. Y., Jain, S., Ring, K., Dai, J., Wang, M. M., Tong, L., Walker, D., & Huang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053569 · Cited by 109
Self-citationApolipoprotein E4 genotype compromises brain exosome production
Peng, K. Y., Pérez-González, R., Alldred, M. J., Goulbourne, C. N., Morales-Corraliza, J., Saito, M., Saito, M., Ginsberg, S. D., Mathews, P. M., & Levy, E. (2019) · Brain · doi:10.1093/brain/awy289 · Cited by 109
Pathogenesis of peritumoral hyperexcitability in an immunocompetent CRISPR-based glioblastoma model
Hatcher, A., Yu, K., Meyer, J. F., Aiba, I., Deneen, B., & Noebels, J. L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133316 · Cited by 114
Ciarlone, S. L., Grieco, J. C., D’Agostino, D. P., & Weeber, E. J. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.002 · Cited by 103
Cheng, J. S., Craft, R., Yu, G.-Q., Ho, K., Wang, X., Mohan, G., Mangnitsky, S., Ponnusamy, R., & Mucke, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115765 · Cited by 100
Liu, D.-S., Pan, X.-D., Zhang, J., Shen, H., Collins, N. C., Cole, A. M., Koster, K. P., Ben Aissa, M., Dai, X.-M., Zhou, M., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0002-2 · Cited by 99
Interindividual variability in response to continuous theta-burst stimulation in healthy adults
Jannati, A., Block, G., Oberman, L. M., Rotenberg, A., & Pascual‐Leone, Á. (2017) · Clinical Neurophysiology · doi:10.1016/j.clinph.2017.08.023 · Cited by 107
APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations
Shinohara, M., Kanekiyo, T., Yang, L., Linthicum, D., Shinohara, M., Fu, Y., Price, L., Frisch‐Daiello, J. L., Han, X., Fryer, J. D., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24628 · Cited by 111
Apolipoprotein E4 produced in GABAergic interneurons causes learning and memory deficits in mice
Knoferle, J., Yoon, S. Y., Walker, D., Leung, L., Gillespie, A. K., Tong, L. M., Bien-Ly, N., & Huang, Y. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.2281-14.2014 · Cited by 97
Self-citationJones, E. A. A., Gillespie, A. K., Yoon, S. Y., Frank, L. M., & Huang, Y. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.056 · Cited by 103
Self-citationThe Role of the GABAergic System in Diseases of the Central Nervous System
Zhang, W., Xiong, B., Zhang, L.-Q., Huang, X., Yuan, X., Tian, Y., & Tian, X. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.06.037 · Cited by 97
Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer’s Disease
Toniolo, S., Sen, A., & Husain, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239318 · Cited by 97
Targeting Neural Hyperactivity as a Treatment to Stem Progression of Late-Onset Alzheimer's Disease
Haberman, R. P., Branch, A., & Gallagher, M. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0541-z · Cited by 98
Hilar GABAergic Interneuron Activity Controls Spatial Learning and Memory Retrieval
Andrews-Zwilling, Y. S., Gillespie, A. K., Kravitz, A. V., Nelson, A., Devidze, N., Lo, I., Yoon, S. Y., Bien‐Ly, N., Ring, K. L., Zwilling, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040555 · Cited by 97
Self-citationVazin, T., Ball, K. A., Lü, H., Park, H., Ataeijannati, Y., Head-Gordon, T. L., Poo, M., & Schaffer, D. V. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.005 · Cited by 94
Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease
Hector, A., & Brouillette, J. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.600084 · Cited by 97
Tweedie, D., Rachmany, L., Rubovitch, V., Lehrmann, E., Zhang, Y., Becker, K. G., Perez, E., Miller, J. P., Hoffer, B. J., Greig, N. H., et al. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.10.001 · Cited by 91
Almeida-Suhett, C. P., Prager, E., Pidoplichko, V. I., Figueiredo, T. H., Marini, A., Li, Z., Eiden, L., & Braga, M. F. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.07.028 · Cited by 78
Wang, C., Cai, X., Wang, R., Zhai, S., Zhang, Y., Hu, W., Zhang, Y., & Wang, D. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01976-1 · Cited by 88
Somatostatinergic systems: an update on brain functions in normal and pathological aging
Martel, G., Dutar, P., Epelbaum, J., & Viollet, C. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00154 · Cited by 86
Gamache, J., Yun, Y., & Chiba-Falek, O. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.045211 · Cited by 84
Tong, L. M., Fong, H., & Huang, Y. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.124 · Cited by 85
Self-citationThe Impact of Estradiol on Neurogenesis and Cognitive Functions in Alzheimer’s Disease
Negah, S. S., Hajali, V., Moradi, H. R., & Gorji, A. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00733-0 · Cited by 83
Riese, F., Gietl, A. F., Zoelch, N., Henning, A., Tuura, R., Kälin, A. M., Leh, S. E., Buck, A., Warnock, G., Edden, R. A. E., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.030 · Cited by 81
Lopatina, O. L., Malinovskaya, N. A., Komleva, Y. K., Gorina, Y. V., Shuvaev, A. N., Olovyannikova, R. Y., Belozor, O. S., Belova, O. A., Higashida, H., & Salmina, A. B. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0014 · Cited by 74
APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease
Wolf, A. B., Caselli, R. J., Reiman, E. M., & Valla, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.011 · Cited by 84
Metadata
- Authors
- Andrews-Zwilling, Y., Bien-Ly, N., Xu, Q., Li, G., Bernardo, A., Yoon, S. Y., Zwilling, D., Yan, T. X., Chen, L., & Huang, Y.
- Affiliations
- University of California, San Francisco (US)
- Gladstone Institutes (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2010-10-13
- Volume
- 30
- Issue
- 41
- Pages
- 13707-13717
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC2988475
- OpenAlex
- W1977434686
- Cited by
- 326
- References
- 66
- Citations by year
- 2026: 20 · 2025: 17 · 2024: 24 · 2023: 22 · 2022: 20 · 2021: 27 · 2020: 26 · 2019: 23 · 2018: 9 · 2017: 20 · 2016: 29 · 2015: 14 · 2014: 24 · 2013: 20 · 2012: 21
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Gladstone Institutes
- National Institutes of Health (1c06rr018928-01, AG‐022074)
- National Institute on Aging (P01AG022074)
- National Center for Research Resources (C06RR18928, C06-RR-018928)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- APOE ε4, Alzheimer's disease, GABAergic interneurons, hilar interneurons, tauopathy, learning and memory impairment, GABAA receptor, pentobarbital, picrotoxin, neurodegeneration, hippocampus, aging
- MeSH terms
- Age Factors, Analysis of Variance, Animals, Cells, Cultured, Electrophysiology, Female, gamma-Aminobutyric Acid, Immunohistochemistry, Interneurons, Memory Disorders, Mice, Transgenic, Nerve Degeneration, Pentobarbital, tau Proteins, Presynaptic Terminals, Statistics, Nonparametric, Maze Learning, Dentate Gyrus, Mice, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
